Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity.
The therapeutic effectiveness and tolerance of 5-aminosalicylic acid (5ASA), compared with Salazosulphapyridine (SASP) in treatment of ulcerative colitis have been evaluated in 86 patients with the disease at a low or medium phase of activity. After a treatment of six weeks, an improvement was noted in 63.6% (5ASA) and 61.3% (SASP) of these patients. However in no case was a complete remission of the disease observed on the basis of endoscopic inspection. In patients with pancolitis the improvement was lower (37.5% with 5ASA, 40% with SASP). The only side-effect was gastric intolerance, which occurred in 18.1% of the 5ASA and in 19% of the SASP patients. In conclusion we can assume that 5ASA and SASP largely overlap each other as regards both therapeutic effectiveness and occurrence of side-effects.
Bresci
G
G
Department of Gastroenterology, Pisa, Italy.
Carrai
M
M
Venturini
G
G
Gambardella
L
L
D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D005773:Gastroscopy; D006801:Humans; D019804:Mesalamine; D013270:Stomach / Q000187:drug effects / Q000473:pathology; D012460:Sulfasalazine / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000636:Aminosalicylic Acids; D012460:Sulfasalazine; D019804:Mesalamine